Loading company…
Syndeio Biosciences develops therapies targeting synaptic dysfunction in neuropsychiatric and cognitive disorders.
Founded in 2025 and based in Indianapolis, US, Syndeio Biosciences develops therapies for neuropsychiatric disorders. Its candidates include Zelquistinel and Apimostinel, with Phase 2 studies underway across nearly 30 locations. The company raised venture funding in May 2025 led by Innoviva and Catalio Capital Management. Other named investors include Tenmile, Luson Bioventures, Palo Santo, Eli Lilly and AbbVie.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in